John Paganelli Acquires 10,000 Shares of OPKO Health (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) Director John Paganelli bought 10,000 shares of the company’s stock in a transaction on Friday, March 20th. The shares were bought at an average price of $1.14 per share, with a total value of $11,400.00. Following the completion of the transaction, the director owned 394,340 shares of the company’s stock, valued at $449,547.60. The trade was a 2.60% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

OPKO Health Price Performance

Shares of NASDAQ:OPK opened at $1.12 on Friday. The company’s fifty day moving average price is $1.23 and its 200-day moving average price is $1.34. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.97 and a quick ratio of 3.52. The firm has a market capitalization of $850.16 million, a price-to-earnings ratio of -3.73 and a beta of 1.50. OPKO Health, Inc. has a one year low of $1.10 and a one year high of $1.83.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. OPKO Health had a negative net margin of 37.19% and a negative return on equity of 17.42%. The company had revenue of $148.50 million during the quarter, compared to the consensus estimate of $139.76 million. During the same period in the previous year, the firm posted $0.01 EPS. The firm’s revenue was down 19.1% compared to the same quarter last year. On average, equities research analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Barrington Research cut their price objective on OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded OPKO Health from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.03.

Hedge Funds Weigh In On OPKO Health

A number of large investors have recently added to or reduced their stakes in OPK. Geode Capital Management LLC boosted its position in OPKO Health by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock valued at $13,940,000 after buying an additional 67,973 shares during the period. Millennium Management LLC increased its holdings in shares of OPKO Health by 39.2% in the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after buying an additional 1,798,385 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of OPKO Health by 150.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after buying an additional 3,600,378 shares during the period. UBS Group AG lifted its stake in shares of OPKO Health by 12.1% in the 4th quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock valued at $6,745,000 after acquiring an additional 577,248 shares during the last quarter. Finally, AWM Investment Company Inc. lifted its stake in shares of OPKO Health by 8.1% in the 2nd quarter. AWM Investment Company Inc. now owns 2,000,000 shares of the biotechnology company’s stock valued at $2,640,000 after acquiring an additional 150,000 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Trending Headlines about OPKO Health

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Director John A. Paganelli purchased 10,000 shares at about $1.14, increasing his stake to 394,340 shares; insider buying can signal management confidence and offer short‑term support. SEC Filing
• Positive Sentiment: Barrington Research kept an Outperform/Buy stance on OPK, which may sustain interest from growth and penny‑stock investors despite other negative headlines. Barrington Article
• Neutral Sentiment: Zacks published thematic commentary noting OPKO’s strengths (RAYALDEE sales, partnerships) but flagged revenue declines and concentration risk — useful context for longer‑term holders evaluating risk/reward. Zacks Hold Article
• Negative Sentiment: Zacks Research sharply cut near‑term EPS estimates across multiple quarters and fiscal years (many quarterly EPS moved to roughly $(0.07)–$(0.08); FY2026/FY2027 lowered to about $(0.29)), signaling weaker expected profitability and raising the bar for operational improvements — a key reason for downward pressure on the stock today.
• Negative Sentiment: Barrington trimmed its price target from $2.25 to $1.50; although the firm left a Buy rating, the lower target reduces measured upside and can weigh on short‑term trader sentiment. InsiderMonkey Article

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.